Moderna announced today, on the occasion of the 5th Vaccines Day event, clinical updates testifying to the advancement and acceleration of its mRNA pipeline.

' We are delighted to announce that four vaccines in our pipeline have achieved successful clinical results', said Stéphane Bancel, CEO of Moderna.

With five vaccines in phase 3 and three more soon to be in phase 3, we have built a very broad and diversified portfolio addressing important unmet medical needs in infectious diseases," he added.

In particular, the Company expects to launch its respiratory syncytial virus (RSV) vaccine in 2024 following FDA approval, a market estimated at some $10 billion annually.

Moderna may also be in a position to deliver the first vaccine against CMV (Cytomegalovirus), with the potential launch of a vaccine in 2026. The CMV market is valued at between $2 and $5 billion a year.

Moderna's vaccine portfolio targets a total addressable market (TAM) of around $52 billion, says the laboratory.

Moderna has also announced a financing, development and commercialization agreement with Blackstone Life Sciences for up to $750 million to advance the influenza program.

Finally, the laboratory adds that R&D will continue to be the Company's top priority in terms of capital allocation.

Copyright (c) 2024 CercleFinance.com. All rights reserved.